- Home
- ENLV vs UBX Comparison
ENLV vs UBX Comparison
Compare ENLV & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLV
- UBX
- Stock Information
- Founded
- ENLV 2005
- UBX 2009
- Country
- ENLV Israel
- UBX United States
- Employees
- ENLV N/A
- UBX N/A
- Industry
- ENLV Biotechnology: Pharmaceutical Preparations
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- ENLV Health Care
- UBX Health Care
- Exchange
- ENLV Nasdaq
- UBX Nasdaq
- Market Cap
- ENLV 20.7M
- UBX 20.4M
- IPO Year
- ENLV 1995
- UBX 2018
- Fundamental
- Price
- ENLV $0.92
- UBX $0.99
- Analyst Decision
- ENLV Strong Buy
- UBX Strong Buy
- Analyst Count
- ENLV 2
- UBX 3
- Target Price
- ENLV $10.00
- UBX $5.33
- AVG Volume (30 Days)
- ENLV 62.6K
- UBX 148.7K
- Earning Date
- ENLV 06-13-2025
- UBX 04-22-2025
- Dividend Yield
- ENLV N/A
- UBX N/A
- EPS Growth
- ENLV N/A
- UBX N/A
- EPS
- ENLV N/A
- UBX N/A
- Revenue
- ENLV N/A
- UBX N/A
- Revenue This Year
- ENLV N/A
- UBX N/A
- Revenue Next Year
- ENLV N/A
- UBX N/A
- P/E Ratio
- ENLV N/A
- UBX N/A
- Revenue Growth
- ENLV N/A
- UBX N/A
- 52 Week Low
- ENLV $0.81
- UBX $0.85
- 52 Week High
- ENLV $1.84
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- ENLV 44.97
- UBX 37.79
- Support Level
- ENLV $0.86
- UBX $0.91
- Resistance Level
- ENLV $0.91
- UBX $1.07
- Average True Range (ATR)
- ENLV 0.06
- UBX 0.09
- MACD
- ENLV 0.00
- UBX 0.03
- Stochastic Oscillator
- ENLV 47.06
- UBX 61.29
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.